Development of a safe and immunogenic anti-chlamydia vaccine for the koala. Many koala populations are under threat of extinction from chlamydial disease.The project will develop a chlamydial vaccine and conduct trials in several wild koala populations for safety and effectiveness.
New models as tools for defining mechanisms of microbe survival in the urogenital tract. Bacteria that infect the human urogenital tract can cause serious disease and these infections represent a large cost to the health-care system world-wide. This study will focus on how bacteria survive in the human urogenital tract and this will impact on strategies aimed at preventing and treating these infections.
Understanding The Role Of The Two Major Bacterial Pathogens In The Upper And Lower Airways Of Indigenous Children With Chronic Lung Disease
Funder
National Health and Medical Research Council
Funding Amount
$743,282.00
Summary
Lung infections are a major disease burden worldwide. Indigenous Australians are affected more; adults with severe lung disease can die in their 30s and 40s. These diseases start early, yet no in-depth studies of bacteria causing lung infections in children have been done. Our expert team proposes to use existing lung fluids from nearly 500 children with chronic lung disease (58% Indigenous), and state-of-the-art laboratory methods, to inform the design of vaccines to prevent lung disease.
Evolution And Pathogenicity Of NDM-1 Positive Escherichia Coli
Funder
National Health and Medical Research Council
Funding Amount
$643,275.00
Summary
Antibiotic resistance (AR), as highlighted by the WHO, is the most pressing medical need of the 21C – some infections are now untreatable. Our research will focus on the new "superbug" NDM-1 positive E. coli. We will correlate AR and pathogenicity and explore the evolution of these "superbugs" using state-of-the-art sequencing. This research will benefit Australian medicine by predicting timelines of AR epidemics and by conducting the first analyses on the virulence potential of these strains.
Uropathogenic Escherichia coli (UPEC) are a major cause of urinary tract infections (UTI) and sepsis. Recently, a highly virulent clone of UPEC (E. coli ST131) that is resistant to multiple types of antibiotics has emerged worldwide. This project addresses the mechanisms by which E. coli ST131 can colonise the urinary tract and cause disease. The outcomes of this project will be a better understanding of how E. coli ST131 causes disease, and potentially new treatment regimes for UTI.
The Darwin Prospective Melioidosis Study: Years 27-31
Funder
National Health and Medical Research Council
Funding Amount
$1,281,718.00
Summary
The Darwin Prospective Melioidosis Study has documented 914 cases since 1989, with 115 fatalities. A surge in Darwin melioidosis cases over the past 5 years has been linked to urban development and the discovery of a new bacterial strain. Whole genome sequencing of our unique 25+ year set of bacteria and their linked patient data will unravel the changing epidemiology and identify important virulence factors, forming a foundation for future diagnostics, therapeutics, and vaccines.
Group A streptococcus (GAS) is a bacteria that causes a wide range of disease in humans. GAS diseases are more common in Australias Indigenous population, and other health and economically disadvantaged groups than more affluent groups. In this study we will evaluate the effectiveness of novel vaccine candidates designed to prevent infection from all strains of GAS.
How bacteria cause disease in the urinary tract. This project will investigate the virulence properties of uropathogenic Escherichia coli, the major causative agent of urinary tract infections (UTI) in humans. The results will help to understand how these bacterial pathogens cause disease and will impact strategies aimed at the prevention and treatment of chronic and recurrent UTI.
Bacterial Pathogenomics: Whole-genome Sequencing To Investigate Infection Transmission, Pathogenesis And Antibiotic Resistance
Funder
National Health and Medical Research Council
Funding Amount
$475,946.00
Summary
As bacterial superbugs – resistant to multiple antibiotics – dominate the headlines, the pipeline for new antibiotics has all but dried up. High-throughput DNA sequencing heralds a golden opportunity for infectious disease research. By studying the entire collection of genes - the genome - of large numbers of multidrug resistant bacterial strains, we aim to better understand the genetic changes that govern the emergence and global spread of superbugs and translate these findings into the clinic.
Innate Immune Signalling In Mycobacterium Tuberculosis Infection
Funder
National Health and Medical Research Council
Funding Amount
$562,857.00
Summary
Tuberculosis (TB) is a major global health threat that causes 1.5 million deaths every year. This study will characterise a new molecular control mechanism that optimises the immune response to the bacteria that cause TB and determine how it contributes to controlling the infection. Such knowledge is essential to help improve patient management and develop better treatments for this devastating disease.